Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729720 | 0.89 | ALDH1A1 (0.43) | BRD4MAPTLMNABRPF1GAA | |
| SCHEMBL22729489 | 0.80 | LMNA (0.39) | BRD4LMNASMN1; SMN2BRPF1GAA | |
| SCHEMBL29839354 | 0.80 | LMNA (0.39) | BRD4LMNASMN1; SMN2BRPF1GAA | |
| SCHEMBL22729670 | 0.78 | NR4A2 (0.53) | NR4A2BRD4MAPTLMNASMN1; SMN2 | |
| SCHEMBL22729649 | 0.77 | KMT2A (0.54) | MAPTLMNASMN1; SMN2BRPF1GAA | |
| SCHEMBL29839305 | 0.77 | KMT2A (0.54) | MAPTLMNASMN1; SMN2BRPF1GAA | |
| SCHEMBL29839363 | 0.75 | UGCG (0.49) | MAPTLMNABRPF1TSHRHSD17B10 | |
| SCHEMBL22729501 | 0.75 | UGCG (0.49) | MAPTLMNABRPF1TSHRHSD17B10 | |
| SCHEMBL22729857 | 0.70 | ALDH1A1 (0.45) | MAPTLMNASMN1; SMN2BRPF1GAA | |
| Methyl 2-Methoxybenzoate SCHEMBL196037 | 0.67 | TSHR (0.69) | MAPTLMNASMN1; SMN2GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | NR4A2 4236/4885BRD4 1170/4885MAPT 356/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | NR4A2 4290/4885BRD4 1201/4885MAPT 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.